A Phase Ib/II Study of the Microenvironment Modifier L-DOS47 Plus Doxorubicin for the Treatment of Patients With Previously Treated Advanced Pancreatic Cancer
Latest Information Update: 12 May 2025
At a glance
- Drugs Doxorubicin (Primary) ; L-DOS 47 (Primary)
- Indications Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Helix BioPharma
Most Recent Events
- 06 May 2025 Status changed from active, no longer recruiting to discontinued.
- 31 Oct 2024 Planned End Date changed from 31 Aug 2025 to 30 Nov 2024.
- 31 Oct 2024 Status changed from recruiting to active, no longer recruiting.